docs/_posts/Ahmetemintek/2022-10-19-ner_covid_trials_en.md
docs/_posts/Ahmetemintek/2022-10-19-ner_jsl_en.md
docs/_posts/Ahmetemintek/2022-10-28-sbiobertresolve_icd10pcs_augmented_en.md
docs/_posts/Ahmetemintek/2022-10-29-icd10cm_mapper_en.md
docs/_posts/Ahmetemintek/2022-10-30-abbreviation_mapper_augmented_en.md
docs/_posts/Ahmetemintek/2022-11-02-icd10cm_resolver_pipeline_en.md
docs/_posts/HashamUlHaq/2022-10-25-t5_base_pubmedqa_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_anatomy_general_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_anatomy_granular_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_biomarker_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_demographics_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_diagnosis_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_posology_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_response_to_treatment_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_test_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_therapy_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_tnm_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_unspecific_posology_en.md
docs/_posts/mauro-nievoff/2022-11-03-oncology_general_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_biomarker_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_diagnosis_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_therapy_pipeline_en.md
docs/_posts/Ahmetemintek/2022-10-19-ner_covid_trials_en.md
docs/_posts/Ahmetemintek/2022-10-19-ner_jsl_en.md
docs/_posts/Ahmetemintek/2022-10-28-sbiobertresolve_icd10pcs_augmented_en.md
docs/_posts/Ahmetemintek/2022-10-29-icd10cm_mapper_en.md
docs/_posts/Ahmetemintek/2022-10-30-abbreviation_mapper_augmented_en.md
docs/_posts/Ahmetemintek/2022-11-02-icd10cm_resolver_pipeline_en.md
docs/_posts/HashamUlHaq/2022-10-25-t5_base_pubmedqa_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_anatomy_general_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_anatomy_granular_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_biomarker_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_demographics_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_diagnosis_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_posology_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_response_to_treatment_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_test_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_therapy_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_tnm_en.md
docs/_posts/mauro-nievoff/2022-10-25-ner_oncology_unspecific_posology_en.md
docs/_posts/mauro-nievoff/2022-11-03-oncology_general_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_biomarker_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_diagnosis_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_therapy_pipeline_en.md
